Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial-mesenchymal transition

Zhang, Zhiwen; Liu, Xiaoding; Huang, Rui; Liu, Xuguang; Liang, Zhiyong; Liu, Tonghua

doi:10.7150/jca.31291



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2019; 10(16):3860-3870. doi:10.7150/jca.31291 This issue Cite

Research Paper

Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial-mesenchymal transition

Zhiwen Zhang, Xiaoding Liu, Rui Huang, Xuguang Liu, Zhiyong Liang^✉, Tonghua Liu^✉

Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.

✉ Corresponding authors: Zhiyong Liang, Department of Pathology, Research Centre for Molecular Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, NO. 1 Shuaifuyuan of Dongcheng Distr More

Citation:

Zhang Z, Liu X, Huang R, Liu X, Liang Z, Liu T. Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial-mesenchymal transition. J Cancer 2019; 10(16):3860-3870. doi:10.7150/jca.31291. https://www.jcancer.org/v10p3860.htm

Other styles

Abstract

The nucleoprotein AHNAK (AHNAK) is a large scaffold protein that is involved in several biological processes. Previous studies have suggested a possible relation between AHNAK and the epithelial-mesenchymal transition (EMT). However, the role of AHNAK in pancreatic ductal adenocarcinoma (PDAC) has not been unveiled. The present study focuses on identifying the potential value of the biological effects of AHNAK in PDAC, which is one of the most lethal malignancies. Bioinformatic analysis was carried for driver gene prediction, and we proved that AHNAK was a driver gene of pancreatic adenocarcinoma and a predictor of poor outcomes of PDAC by clinical characteristics analysis and in vitro experiments. High AHNAK expression was associated with short disease-free survival and poor overall survival. In vitro assays showed that AHNAK was associated with cell proliferation and migration, and a positive relation was observed between AHNAK and the EMT. In conclusion, AHNAK is a crucial biomarker that may promote cellular proliferation and migration and thus impact PDAC outcomes via the EMT, which suggests that AHANK might be a potential target for PDAC.

Keywords: Pancreatic ductal adenocarcinoma, nucleoprotein AHNAK, prognosis, epithelial mesenchymal transition

Citation styles

APA

Zhang, Z., Liu, X., Huang, R., Liu, X., Liang, Z., Liu, T. (2019). Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial-mesenchymal transition. Journal of Cancer, 10(16), 3860-3870. https://doi.org/10.7150/jca.31291.

ACS

Zhang, Z.; Liu, X.; Huang, R.; Liu, X.; Liang, Z.; Liu, T. Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial-mesenchymal transition. J. Cancer 2019, 10 (16), 3860-3870. DOI: 10.7150/jca.31291.

NLM

CSE

Zhang Z, Liu X, Huang R, Liu X, Liang Z, Liu T. 2019. Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial-mesenchymal transition. J Cancer. 10(16):3860-3870.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.